UNSPSC 51162640: Nonivamide

This classification denotes a capsaicin analog, nitric oxide synthase antagonist and inhibitor, and sensory system agent with the molecular formula C17H27NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) S846B891OR, chemically known as nonanamide, n-vanillyl- (8ci) but more generally known as nonivamide, which bears US NIH Compound Identifier 2998. European Medicines Agency schedules Nonivamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09352MIG.

UNSPSC 51162640 Nonivamide is a Commodity code nominally designating a specific chemical compound, but recent state and local procurement activity under this code does not reflect purchases of nonivamide itself. Instead, the code tags solicitations for naloxone (opioid antagonist) and generic multi-source pharmaceuticals, suggesting a significant mismatch between the code's nominal scope and actual buying patterns. State and local health departments and cooperative purchasing alliances are the primary issuing bodies using this code, though the pharmaceutical products being procured diverge substantially from the chemical compound the code purports to describe.

Geographic activity centers on Florida and Minnesota, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administering a regional pharmaceutical contract spanning participating state and local facilities including Oregon. Representative recent opportunities include Seminole County, Florida's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a two-year initial term plus one-year renewal option; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co.), with contracts effective July 1, 2026. The code shows limited recent relevant activity, and the mismatch between nonivamide and the naloxone and generic pharmaceutical products actually being bought suggests either miscoding in the posting systems or a coding convention not aligned with the chemical specificity the UNSPSC structure implies.